Which therapy has the potential to depress growth and bone mineral density in children with Crohn's disease?

Which therapy has the potential to depress growth and bone mineral density in children with Crohn's disease?

• A. Corticosteroids
• B. Exclusive Enteral Nutrition
• C. Parenteral Nutrition
• D. Anti-TNF Therapy

Answer: (A)

Corticosteroids can blunt growth and bone health in children with Crohn's disease. In growing kids, height gain depends on the growth hormone/IGF-1 axis and healthy activity at the growth plates, along with adequate bone formation. Systemic steroids interfere with this process in several ways: they directly inhibit osteoblasts, stimulate osteoclasts, and disrupt the growth plate's ability to proliferate, leading to slower linear growth. They also reduce calcium absorption from the gut and increase calcium loss by the kidneys, which lowers bone formation and promotes bone resorption. The combined effect is a decline in growth velocity and a lowering of peak bone mass, increasing the risk of osteoporosis later on. In Crohn's disease, inflammation, malnutrition, and nutrient losses already threaten growth and bone density, so adding long-term corticosteroid exposure compounds these problems. Other therapies are less likely to depress growth: exclusive enteral nutrition supports proper nutrition and has been shown to improve growth outcomes and bone health in children; anti-TNF therapy reduces inflammatory burden and often allows catch-up growth and better bone density; parenteral nutrition provides necessary calories and nutrients when enteral feeding isn’t possible and is not inherently growth-suppressive.

Corticosteroids can blunt growth and bone health in children with Crohn's disease. In growing kids, height gain depends on the growth hormone/IGF-1 axis and healthy activity at the growth plates, along with adequate bone formation. Systemic steroids interfere with this process in several ways: they directly inhibit osteoblasts, stimulate osteoclasts, and disrupt the growth plate's ability to proliferate, leading to slower linear growth. They also reduce calcium absorption from the gut and increase calcium loss by the kidneys, which lowers bone formation and promotes bone resorption. The combined effect is a decline in growth velocity and a lowering of peak bone mass, increasing the risk of osteoporosis later on.

In Crohn's disease, inflammation, malnutrition, and nutrient losses already threaten growth and bone density, so adding long-term corticosteroid exposure compounds these problems. Other therapies are less likely to depress growth: exclusive enteral nutrition supports proper nutrition and has been shown to improve growth outcomes and bone health in children; anti-TNF therapy reduces inflammatory burden and often allows catch-up growth and better bone density; parenteral nutrition provides necessary calories and nutrients when enteral feeding isn’t possible and is not inherently growth-suppressive.